Stock Market Reviews

VCEL (Vericel Corporation) News

Get the latest news, insights, and market updates on VCEL (Vericel Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• US High Growth Tech Stocks with Promising Potential
  As the U.S. stock market experiences a downturn with the S&P 500 closing lower for four consecutive sessions and tech stocks under pressure, investors are keenly observing key earnings reports and economic indicators that could impact future performance. In this environment, identifying high growth tech stocks with strong fundamentals and innovative potential becomes crucial for navigating market volatility effectively.
  Nov 19, 2025 - $VCEL
• Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
  CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at 11:00 a.m. ET (10:00 a.m. CT) on Thursday, November 20, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. A
  Nov 14, 2025 - $VCEL
• Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade
  The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Nov 10, 2025 - $VCEL
• Vericel (VCEL) Is Up 10.5% After Record Q3 Profit and MACI Sales Acceleration – What's Changed
  Vericel Corporation recently reported record third-quarter 2025 results, posting US$67.5 million in revenue and turning a net profit of US$5.07 million, while reaffirming its full-year revenue guidance of US$272 million to US$276 million. A standout insight is the strong 25% year-over-year growth in MACI sales, alongside continued progress in pipeline initiatives such as the upcoming MACI Ankle clinical study and international commercialization plans. With third-quarter revenue and...
  Nov 7, 2025 - $VCEL
• A Fresh Look at Vericel (VCEL) Valuation Following Recent Share Price Rebound
  Vericel (VCEL) shares have experienced some movement lately, prompting investors to revisit the company’s fundamentals and recent performance trends. Knowing how returns stack up over the past month and year helps frame where sentiment stands today. See our latest analysis for Vericel. Vericel’s 1-month share price return of 13.54% shows a strong rebound in momentum, even as the stock is still working to recover from a tough year with a one-year total shareholder return of -28.24%. Despite...
  Nov 7, 2025 - $VCEL
• Vericel Corp (VCEL) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
  Vericel Corp (VCEL) surpasses revenue expectations with strong Macy performance, while preparing for future growth amidst market uncertainties.
  Nov 6, 2025 - $VCEL
• Assessing Vericel After FDA Approval and a 10% Rally in 2025
  Curious if Vericel is a hidden gem or just another biotech story? Let’s dive into what really determines whether this stock deserves a spot in your portfolio. After a tough year, with shares down 22.6% over the past 12 months and 32.5% year to date, Vericel has bounced back lately. The stock has climbed 6.7% in the last week and 10.3% over the past month. Part of the recent momentum seems tied to positive news around advancements in cell therapy and a fresh FDA nod that has investors feeling...
  Nov 6, 2025 - $VCEL
• Vericel Reports Third Quarter 2025 Financial Results
  Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported fi
  Nov 6, 2025 - $VCEL
• Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates
  Vericel (VCEL) delivered earnings and revenue surprises of +600.00% and +5.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $VCEL
• Vericel (VCEL) Q3 2025 Earnings Call Transcript
  The company delivered outstanding financial and business results in the third quarter, with strong top-line revenue growth and even higher profit growth, a significant inflection in operating cash flow, and continued progress across a number of key business initiatives. Record third-quarter MACI revenue increased 25% over last year, and the highest quarterly burn care revenue of the year, as Epicel had one of its highest revenue quarters to date. NexoBird had its highest quarterly revenue since launch.
  Nov 6, 2025 - $VCEL